You cannot register for this webinar

Thursday, January 30, 2025 10:00 am ET / 15:00 UTC Featuring: Sabina Burlă, PhD - Chief Scientific Officer, Invitrolize Arno Gutleb, PhD - Managing Director, Invitrolize An in vitro model for the identification of respiratory sensitizers, ALIsens®, was developed at the Luxembourg Institute of Science and Technology (LIST). ALIsens®, a complex three-dimensional (3D) model, is built using human cell lines: alveolar type II epithelial (A549), endothelial (EA.hy926) and monocytes (THP-1). The cellular architecture within the test system favors the development of a tissue-like microenvironment by cell-to-cell direct communication and indirectly through the secreted messenger molecules. Additionally, it facilitates the exposure of respiratory sensitizers in a more realistic approach, at the air-liquid-interface (ALI). The model has been shown to correctly identify respiratory sensitizers belonging to acid anhydrides chemical class and differentiate them from skin sensitizers and non-sensitizers based on the increased expression of markers of the surface of dendritic-like cells, thymic stromal lymphopoietin receptor (TSLPr), cluster or differentiation (CD)86 and CD54, the profile of secreted messenger molecules (cytokines and chemokines) and gene expression. To establish accurate sensitizer classification, a threshold for TSLPr cell surface marker must be defined. The model’s accuracy, sensitivity and specificity of the model will be evaluated within a broader context, utilizing data from exposures to respiratory and skin sensitizers as well as non-sensitizers. This comprehensive approach aims to enhance the predictive power and reliability of ALIsens® for distinguishing respiratory from skin sensitizers and from non-sensitizers across different exposure types. For complete details, please visit https://PCRM.org/NURA. The materials and resources from this webinar will also be posted to https://PCRM.org/NAMSpotlight.